Misleading NDAs Beget Closer Scrutiny From FDA Staff – OND Chief Jenkins
This article was originally published in The Tan Sheet
Executive Summary
Successful appeals of NDA rejections are rare, Office of New Drugs Director John Jenkins acknowledges, but he advises pharmaceutical firms that submitting misleading applications only increases the odds against success